HOME >> BIOLOGY >> NEWS
Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) , announced today the commercial introduction of a patented, non-invasive test, CRSFungal Profile, by its specialty pharmaceuticals division, TEAMM Pharmaceuticals, to assist in the diagnosis of Chronic Sinusitis (CS) otherwise known as Chronic Rhinosinusitis (CRS). In partnership with the licensee for this patented technology, IMMCO Diagnostics Inc. (IMMCO) of Buffalo, NY, Accentia Biopharmaceuticals is making CRSFungal Profile available to ear, nose and throat (ENT) specialists and allergists nationwide.

CS is one of the most common chronic diseases suffered by Americans today, affecting an estimated 31 million patients in the US. CS is a chronic inflammatory disease of the nasal and sinus mucosa that persists for greater than three months. Long-term consequences include the formation of inflammatory polyps in the nose. The inflammation of CS results in symptoms that include nasal congestion, mouth breathing, nasal discharge, and post-nasal drip. This chronic non-infectious inflammation predisposes patients to acute exacerbations of their sinusitis due to bacterial superinfection, which requires oral antibiotic therapy. Many patients with severe disease resort to sinus surgery in an effort to reduce nasal obstruction and improve sinus drainage. Historically, the diagnosis of CS has been made based on a doctor's subjective assessment of a combination of the patients' symptoms, nasal endoscopy, and CT scan of the sinuses. There has been no confirmatory diagnostic test for the disease. Published studies by researchers at the Mayo Clinic in Rochester, Minnesota have provided substantial evidence that the underlying cause for CS is the presence of fungi, in the mucus layer of the nasal and sinus cavities. While fungi are present in the majority of the population, it is an inflammatory response in susceptible patients that causes CS. This research has led to a better understanding of the condition and
'"/>

Contact: Leslie Gwinn
lgwinn@sciwords.com
202-518-6578
SciWords
29-Nov-2005


Page: 1 2

Related biology news :

1. FDA grants Accentia Biopharmaceuticals...
2. Accentia Biopharmaceuticals announces option agreement with Mayo
3. AutovaxID-C introduced by Accentia Biopharmaceuticals
4. Accentia Biopharmaceuticals acquires exclusive license
5. Springer launches Theoretical Ecology
6. NCRR launches national network to connect investigators based at minority institutions
7. Scientific American launches innovative new version of magazine
8. University of Arizona launches major scientific research initiative at Biosphere 2
9. Brazils first oncology biotech launches
10. University of Liverpool launches 10 million small animal teaching hospital
11. UCI launches effort to develop patient-specific stem cell lines

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... July 16, 2020 , ... A ... of the Invictus Medical Neoasis™ active noise control device to attenuate typical noises ... the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and other ...
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics Biomedical (ABM), a ... awards for not only the products and treatments developed, but also the dedicated ... RF. All the brands built by ABM have received several honors already for ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a ... most common and aggressive adult brain cancer—announced today the appointments of its first ... charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows are ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... (PRWEB) , ... August 12, 2020 , ... ... Inc. (EMMA International), a global leader in FDA compliance consulting has been ... nation’s fastest-growing private companies. The list represents a unique look at the most ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive ... patients may choose which extremities they would like treated. , Several studies have shown ... At R3 International, umbilical cord tissue is obtained from a lab with a long ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing ... announced that they have entered into a strategic partnership whereby Catalent will provide ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech ... Regulatory Solutions, in a one hour live webinar on Thursday, August 13, ... China for drugs and medical devices. Specifically, for medical devices, the NMPA has departments ...
Breaking Biology Technology:
Cached News: